Trial Profile
A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2020
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 08 May 2019 Status changed from active, no longer recruiting to completed.
- 17 Apr 2019 Planned End Date changed from 1 Feb 2019 to 30 Apr 2019.
- 17 Apr 2019 Planned primary completion date changed from 1 Feb 2019 to 30 Apr 2019.